- Home
- PHIO vs CERO Comparison
PHIO vs CERO Comparison
Compare PHIO & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- CERO
- Stock Information
- Founded
- PHIO 2011
- CERO 2017
- Country
- PHIO United States
- CERO United States
- Employees
- PHIO N/A
- CERO N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- PHIO Health Care
- CERO
- Exchange
- PHIO Nasdaq
- CERO Nasdaq
- Market Cap
- PHIO 8.0M
- CERO 8.4M
- IPO Year
- PHIO N/A
- CERO N/A
- Fundamental
- Price
- PHIO $1.67
- CERO $1.79
- Analyst Decision
- PHIO Strong Buy
- CERO
- Analyst Count
- PHIO 1
- CERO 0
- Target Price
- PHIO $36.00
- CERO N/A
- AVG Volume (30 Days)
- PHIO 981.0K
- CERO 745.6K
- Earning Date
- PHIO 04-01-2025
- CERO 03-04-2025
- Dividend Yield
- PHIO N/A
- CERO N/A
- EPS Growth
- PHIO N/A
- CERO N/A
- EPS
- PHIO N/A
- CERO N/A
- Revenue
- PHIO N/A
- CERO N/A
- Revenue This Year
- PHIO N/A
- CERO N/A
- Revenue Next Year
- PHIO N/A
- CERO N/A
- P/E Ratio
- PHIO N/A
- CERO N/A
- Revenue Growth
- PHIO N/A
- CERO N/A
- 52 Week Low
- PHIO $1.53
- CERO $1.57
- 52 Week High
- PHIO $10.35
- CERO $1,095.00
- Technical
- Relative Strength Index (RSI)
- PHIO 42.10
- CERO 36.41
- Support Level
- PHIO $1.64
- CERO $1.70
- Resistance Level
- PHIO $1.88
- CERO $2.10
- Average True Range (ATR)
- PHIO 0.13
- CERO 0.23
- MACD
- PHIO -0.02
- CERO 0.23
- Stochastic Oscillator
- PHIO 5.61
- CERO 33.85
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.